Business, energy, technology, markets and global industry news from Business News Today

AMP2

PharmaDeviceNews AMP2
Representative image of lumbar spinal fusion surgery and bone regeneration technology, illustrating Theradaptive’s OsteoAdapt SP pivotal OASIS trial and its potential role in advancing next-generation orthobiologics for degenerative spinal disease.
Medical Devices & Diagnostics

FDA clears Theradaptive’s OASIS pivotal trial as spinal fusion graft race enters a new phase

Spine biologics has long lacked fresh competition. Theradaptive’s OsteoAdapt SP trial could test whether that market is ready to move.

Read More
Medical Devices & Diagnostics

Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026

ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.

Read More